摘要
代谢组学是20世纪末逐渐发展起来的一门组学技术。它作为系统生物学的一部分，正广泛应用于包括肿瘤在内的各种疾病的诊断、治疗、预后等方面。肺癌是发病率和病死率最高的肿瘤，肺癌的早期和晚期发现在患者5年生存率上差异巨大，故肺癌的早期诊断意义重大。代谢组学除了应用于确定肺癌诊断的标志物，也可应用于确定肺癌的预后及治疗措施毒性或有效性的相关标志物。后者使得肺癌患者的治疗更加个体化成为可能。同时代谢组学研究也使得我们对肺癌的病理生理过程理解得更加深入。本文就代谢组学的定义和研究方法、代谢组学两大主要技术平台核磁共振和质谱的特点及其在肺癌中的应用作一综述。
Metabolomics is one of omics technologies, which is gradually developed from the late 20th century. As a part of the systems biology, metabolomics is being widely used in the diagnosis, treatment, prognosis, and other aspects of various diseases,including cancer. Lung cancer is the tumor with the highest incidence and mortality Five years survival rate differs significantly from early to late diagnosis. Metabolomics is used to identify the diagnostic biomarkers of lung cancer, it is also used to define biomarkers related to prognosis or toxicity/efficacy of therapeutic interventions. The latter makes the treatment of patients with lung cancer may become more individualized. At the same time, metabonomics allows to understand the pathophysiology of lung cancer in more depth. In this paper, definitions, methods of the metabonomics, two major technology platforms nuclear magnetic resonance and mass spectrometry and their application in lung cancer are reviewed.
出处
《国际呼吸杂志》
2015年第6期460-464,共5页
International Journal of Respiration
关键词
代谢组学
肺癌
核磁共振
质谱
Metabonomics
Lung cancer
Nuclear magnetic resonance
Mass spectrometry
